US-based pharmaceutical company DifGen Pharmaceuticals LLC announced on Tuesday the successful completion of the European Decentralised Procedure (DCP) for Tafamidis 61 mg Capsules, marking the company's first major regulatory milestone in Europe.
Building on this regulatory milestone, DifGen intends to engage with established pharmaceutical companies across Europe to evaluate potential licensing, regulatory and strategic collaboration opportunities.
DifGen is investing in complex generics, specialty pharmaceutical products and differentiated dosage forms, supported by its manufacturing and research and development infrastructure in Florida.
Henlius and Sandoz expand biosimilars collaboration
Aurisco Pharmaceutical reports successful US FDA inspection
Dr. Reddy's launches first-to-market sugammadex injection in the US
Par Health launches generic version of Janumet XR tablets in US
EQL Pharma gains approval to sell Mellozzan in Kazakhstan
Newbury Pharmaceuticals receives Swedish approval for generic tofacitinib
Lupin announces US launch of Azilsartan Medoxomil Tablets
Breckenridge launches Tofacitinib Tablets, generic equivalent to Pfizer's Xeljanz
Hims & Hers expands GLP-1 offering in Canada with generic semaglutide
Apotex announces commercial launch of Apo-Semaglutide Injection in Canada
Transpire Bio's generic high-strength Trelegy Ellipta ANDA accepted for filing by US FDA
Kaiser Permanente reports study findings showing significant cost savings
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cipla's AB-rated Ventolin HFA generic receives US FDA approval